These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2459032)

  • 1. Prevention of experimental coronary thrombosis by hirudin.
    Bucha E; Nowak G; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):52-8. PubMed ID: 2459032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic and haemorrhagic effects of the naturally occurring thrombin inhibitor hirudin.
    Kaiser B; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):41-6. PubMed ID: 2459030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of arterial thrombus formation in two canine models: comparison of ancrod, a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotein 11b/IIIa-receptor antagonist Ro 43-8857.
    Rübsamen K; Hornberger W; Kirchengast M
    Thromb Haemost; 1995 Nov; 74(5):1353-60. PubMed ID: 8607122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
    Rote WE; Mu DX; Bates ER; Nedelman MA; Lucchesi BR
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):203-11. PubMed ID: 7511748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
    Krupinski K; Breddin HK
    Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in the controlled release systems of hirudin].
    Li T; Wan C; Li Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 1998 Dec; 15(4):419-23. PubMed ID: 12552793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
    Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
    Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological studies on the antithrombotic action of hirudin in experimental animals.
    Markwardt F; Hauptmann J; Nowak G; Klessen C; Walsmann P
    Thromb Haemost; 1982 Jun; 47(3):226-9. PubMed ID: 7112494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic action of recombinant hirudin in a venous thrombosis model.
    Raake W; Klauser RJ; Elling H; Zeiller P
    Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis.
    Ohyama T; Hori T; Moriike M; Asano T; Hayashi H; Iwade K; Hosoda S
    Thromb Haemost; 1998 Feb; 79(2):423-30. PubMed ID: 9493602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model.
    Sorg H; Hoffmann JN; Menger MD; Lindenblatt N; Goehring P; Vollmar B
    Thromb Haemost; 2006 Sep; 96(3):371-7. PubMed ID: 16953281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
    Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of thrombus formation by endothelin-1 in canine models of arterial thrombosis.
    Leadley RJ; Humphrey WR; Erickson LA; Shebuski RJ
    Thromb Haemost; 1995 Dec; 74(6):1583-90. PubMed ID: 8772241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic studies with recombinant hirudin in dogs.
    Nowak G; Markwardt F; Fink E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):70-4. PubMed ID: 2459035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
    Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
    Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization.
    Liu Y; Lu WL; Wang JC; Zhang X; Zhang H; Wang XQ; Zhou TY; Zhang Q
    J Control Release; 2007 Feb; 117(3):387-95. PubMed ID: 17207884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.
    Cirillo R; Lippi A; Subissi A; Agnelli G; Criscuoli M
    Thromb Haemost; 1996 Sep; 76(3):384-92. PubMed ID: 8883275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.